Skip to main content

Advertisement

Table 1 Characteristics of the 98 MDS patients treated with decitabine

From: High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome

Characteristics Category
Median age (range) 62 (20–82)
Sex, n (%)
 Male 69 (70)
 Female 29 (30)
WHO/FAB classification, n (%)
 RCMD 19 (20)
 RAS 2 (3)
 RAEB-1 25 (22)
 RAEB-2 29 (30)
 RAEB-t 14 (17)
 CMML 9 (8)
Karyotypes, n(%)
 Normal 49 (50)
 +8 7 (7)
 −7/7q- 9 (9)
 −5/5q- 2 (2)
 20q- 5 (5)
 Complex 13 (13)
 Others 13 (13)
International prognostic scoring system, n (%)
 Low 4 (4)
 Intermediate-1 33 (34)
 Intermediate-2 34 (35)
 High 27 (27)
  1. MDS myelodysplastic syndrome, FAB French-American-British, WHO world health organization, RCMD refractory cytopenia with multilineage dysplasia, RAS refractory anemia with ringed sideroblasts, RAEB refractory anemia with excess of blasts, RAEB-t refractory anemia with excess of blasts in transformation, CMML chronic myelomonocytic leukemia